BioSpace News Archive

SensaSure Technologies and Verde Bio Holdings Provide Update on Pending Merger.

Immutep Limited today announces preliminary topline results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alpha (efti) in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma patients (1L HNSCC) with negative PD-L1 expression.

Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the results of an implementation study conducted by researchers at University Medical Center Groningen that compared optical genome mapping (OGM) to traditional cytogenetic methods for the detection of structural variants (SVs) in bone marrow aspirate (BMA) samples.

GV20 Therapeutics today announced the publication of a peer-reviewed article titled, " IGSF8 is an innate immune checkpoint and cancer immunotherapy target " in the journal Cell.

Lykos Therapeutics announced the completion of a European Phase 2 study (MP18), an open-label, multicenter feasibility study of investigational midomafetamine (MDMA) capsules used in combination with psychological intervention (“MDMA-assisted therapy”) for adults with post-traumatic stress disorder (“PTSD”).

Chiesi Global Rare Diseases today announced the publication of results from a Fabry disease patient survey in the peer-reviewed Orphanet Journal of Rare Diseases.

Lantern Pharma Launches “ Webinar Wednesdays ” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development.

Travere Therapeutics, Inc., and CSL Vifor announced that the European Commission has granted conditional marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day.

Alkermes plc announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with narcolepsy type 1.

REGENXBIO Inc. announced it will participate in Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024.